Skip to main content
Clinical Trials/NCT03819608
NCT03819608
Recruiting
Not Applicable

Neuromodulation and Neurorehabilitation for Treatment of Functional Deficits After mTBI and PTSD

Northwestern University2 sites in 1 country200 target enrollmentApril 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mild Traumatic Brain Injury
Sponsor
Northwestern University
Enrollment
200
Locations
2
Primary Endpoint
Change in the Mayo Portland Adaptability Inventory (MPAI)
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This study will determine (i) the magnitude of immediate and sustained effects of a current clinical standard interactive computer attention processing training (APT) when combined with intermittent theta burst stimulation (iTBS), a type of repetitive transcranial magnetic stimulation and (ii) determine how APT + iTBS changes the neurocognitive system of attention in individuals with persistent attention deficits related to mTBI +/- PTSD.

Registry
clinicaltrials.gov
Start Date
April 1, 2021
End Date
December 2025
Last Updated
last year
Study Type
Interventional
Study Design
Factorial
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Theresa Pape

Research Health Scientist

Northwestern University

Eligibility Criteria

Inclusion Criteria

  • At least 18 years of age and no older than 80 years of age
  • 3 months post exposure to mTBI event
  • Have a history of mTBI with PTSD OR mTBI without PTSD as defined by formalized measures to classify mTBI based on the Symptom Attribution and Classification Algorithm (SACA) and the PTSD Module L of the SCID
  • Endorse at least moderate severity on at least one of the four cognitive complaints in the Neurobehavioral Symptom Inventory

Exclusion Criteria

  • Participating in another research study
  • Non-fluent in English (speaking and reading)
  • History of epilepsy pre-injury
  • Receiving antiepileptic treatment for documented active seizures in the past 6 months
  • Taking medications that lower seizure threshold including antipsychotics, trazodone and tramadol
  • History of surgery on blood vessels in brain and/or valves of the heart
  • History of brain hemorrhage, neurovascular conditions and neurodegenerative disorders
  • History or current diagnosis of psychotic spectrum disorders (i.e. bipolar, schizophrenia)
  • Significant heart disease as determined by physician review of medical chart
  • Pregnant at time of enrollment or any time during study participation

Outcomes

Primary Outcomes

Change in the Mayo Portland Adaptability Inventory (MPAI)

Time Frame: baseline, 5 weeks, 10 weeks, 20 weeks

Self-reported ability, adjustment and community participation. It is comprised of 30 items and three subscales: Ability Index, Adjustment Index and Participation Index. Items are scored on a 5-point Likert scale, with lower scores indicating higher levels of functioning.

Secondary Outcomes

  • change in the PTSD Checklist (PCL)(baseline, 5 weeks, 10 weeks, 20 weeks)

Study Sites (2)

Loading locations...

Similar Trials